T-ALL cell lines showing high IC50 to nelarabine treatment were treated for 6, 16, 24, 48 h with the drug (10 μM) and then analyzed by western blotting for the activation of PI3K/AKT/mTOR or MEK/ERK pathways. The gene discussed is MAP2K7; the disease is acute lymphoblastic leukemia.